The $18M upfront eliminates near-term bankruptcy risk and provides capital for pipeline advancement or M&A. Watch for announcements on new product acquisitions or Nasdaq compliance progress. The milestone payments are contingent on Talicia sales under Apotex and may take years to materialize.
Price Chart
Executive Summary
RedHill Biopharma divests its 70% stake in Talicia to Apotex for $18M upfront plus up to $35M in milestones, directly addressing the going-concern risk flagged in the prior 20-F. The $18M cash infusion (4.5x current market cap) provides immediate liquidity to fund pipeline development and potential acquisitions, though the company loses its only commercial product and ongoing Talicia revenue.
Key Facts
- RedHill sold its 70% interest in Talicia Holdings Inc. to Apotex for $18M upfront cash
- Up to $35M in additional milestone payments based on worldwide net sales
- Apotex previously acquired Cumberland's 30% stake, now owns 100% of Talicia
- RedHill entered a 6-month transition services agreement with 3-month extension option
- Five-year non-compete covenant on Talicia in the U.S. and territories
- Prior 20-F (April 2026) reported only $4.1M cash and substantial going concern doubt
Financial Impact
$18M upfront cash infusion (4.5x $4M market cap) plus up to $35M contingent milestones; prior cash was $4.1M per 20-F
Risk Factors
- Loss of Talicia's ongoing commercial revenue stream
- Milestone payments are contingent and uncertain
- Nasdaq minimum bid price compliance remains unresolved
- Pipeline programs (opaganib, RHB-102, RHB-204, RHB-107) are early-stage with no near-term revenue
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-004329 |
| Document: zk2636045.htm | 0001178913-26-004329 |
| Document: 0001178913-26-004329-index-headers.html | 0001178913-26-004329 |
| Document: 0001178913-26-004329-index.html | 0001178913-26-004329 |
| Document: 0001178913-26-004329.txt | 0001178913-26-004329 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 21, 2026 5d ago | 6-K | $0.4550 | awaiting T+60 | — | $0.4230 (−7.03%) |
Oct 19, 2026 7d ago | 6-K | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 19, 2026 7d ago | Press Release | $0.5012 | awaiting T+60 | — | $0.4230 (−15.60%) |
Oct 13, 2026 12d ago | 6-K | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 13, 2026 12d ago | 424B5 | $0.4862 | awaiting T+60 | — | $0.4230 (+13.00%) |
Oct 7, 2026 19d ago | 6-K | $0.4740 | awaiting T+60 | — | $0.4230 (−10.76%) |
Sep 1, 2026 7w ago | 6-K | $0.8700 | awaiting T+60 | — | $0.4230 (−51.38%) |
Aug 31, 2026 8w ago | 6-K | $0.9000 | awaiting T+60 | — | $0.4230 (−53.00%) |
Aug 7, 2026 11w ago | 6-K | $0.6050 | awaiting T+60 | — | $0.4230 (−30.08%) |
Aug 6, 2026 11w ago | 6-K | $0.5810 | awaiting T+60 | — | $0.4230 (−27.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers